These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 23826755)
21. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity. Salem K; Brown CO; Schibler J; Goel A Exp Hematol; 2013 Feb; 41(2):209-18. PubMed ID: 23063726 [TBL] [Abstract][Full Text] [Related]
22. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways. Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572 [TBL] [Abstract][Full Text] [Related]
23. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630 [TBL] [Abstract][Full Text] [Related]
24. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945 [TBL] [Abstract][Full Text] [Related]
25. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581 [TBL] [Abstract][Full Text] [Related]
26. Suppression of proteasome induces apoptosis in APL cells and increases chemo-sensitivity to arsenic trioxide: Proposing a perception in APL treatment. Zamani-Moghaddam N; Mousavi FS; Esmaeili S; Yousefi AM; Safaroghli-Azar A; Bashash D Cancer Treat Res Commun; 2021; 26():100284. PubMed ID: 33387871 [TBL] [Abstract][Full Text] [Related]
27. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines. Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625 [TBL] [Abstract][Full Text] [Related]
29. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities. Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668 [TBL] [Abstract][Full Text] [Related]
30. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835 [TBL] [Abstract][Full Text] [Related]
31. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Paoluzzi L; Gonen M; Bhagat G; Furman RR; Gardner JR; Scotto L; Gueorguiev VD; Heaney ML; Manova K; O'Connor OA Blood; 2008 Oct; 112(7):2906-16. PubMed ID: 18591385 [TBL] [Abstract][Full Text] [Related]
32. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells. Piedfer M; Bouchet S; Tang R; Billard C; Dauzonne D; Bauvois B Biochim Biophys Acta; 2013 Jun; 1833(6):1316-28. PubMed ID: 23481040 [TBL] [Abstract][Full Text] [Related]
33. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600 [TBL] [Abstract][Full Text] [Related]
34. Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines. Takahashi K; Inukai T; Imamura T; Yano M; Tomoyasu C; Lucas DM; Nemoto A; Sato H; Huang M; Abe M; Kagami K; Shinohara T; Watanabe A; Somazu S; Oshiro H; Akahane K; Goi K; Kikuchi J; Furukawa Y; Goto H; Minegishi M; Iwamoto S; Sugita K PLoS One; 2017; 12(12):e0188680. PubMed ID: 29236701 [TBL] [Abstract][Full Text] [Related]
35. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023 [TBL] [Abstract][Full Text] [Related]
36. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189 [TBL] [Abstract][Full Text] [Related]